Introduction
Extracorporeal membrane oxygenation (ECMO) in veno-arterial configuration represents an increasingly used method for circulatory support. Extracorporeal blood flow may exceed 5 L/min and veno-arterial ECMO can, therefore, either support or fully substitute the cardiac pump and pulmonary gas exchange.
1 ECMO has been used for many years in neonates and infants with pulmonary hypertension and severe respiratory failure.
2 -5 During the past two decades increasing number of reports has been published showing successful application of veno-arterial ECMO also in adult patients with rapidly progressing severe cardiogenic shock 6 -11 or with refractory cardiac arrest.
9,11 -20 Current clinical Guidelines of the European Society of Cardiology recommend consideration of ECMO use in patients with cardiogenic shock, remaining unstable despite administration of inotropes, vasopressors, ventilatory support, reperfusion and revascularization 21 or as a "bridge to decision" to stabilize hemodynamics. 22 However, this recommendation is based on expert consensus. Currently, there are no prospective randomized trials available, focusing on the use of ECMO in patients with severe cardiogenic shock. 9 -11 Therapy with veno-arterial ECMO in cardiogenic shock offers rapid improvement of circulatory status and significant increase in tissue perfusion. On the other hand, ECMO is an invasive method, requiring anticoagulation, and the use of ECMO is, therefore, associated with possible complications, i.e. bleeding or leg ischemia. 23 Veno-arterial ECMO may also negatively influence the left ventricular functions. 24 Furthermore, implantation of ECMO represents also considerable financial costs and mortality remains high despite the improvement of circulatory status. 25, 26 The aim of the ExtraCorporeal Membrane Oxygenation in the therapy of Cardiogenic Shock (ECMO-CS) trial is to compare two recognized therapeutic approaches in the management of severe cardiogenic shock: early conservative therapy and early implantation of veno-arterial ECMO on the background of standard care.
Study design Overview
The ECMO-CS is a multi-center randomized prospective trial focused on the efficacy of ECMO in the therapy of advanced cardiogenic shock. The trial was approved by Ethics Committees of all participating centers and is registered at ClinicalTrials.gov with No. NCT02301819. First subject was randomized in 2014 and the last patient-last visit is projected to 2019.
Eligible patients for ECMO-CS trial have rapidly deteriorating or severe cardiogenic shock defined in inclusion criteria ( Table 1 ) and do not meet exclusion criteria ( Table 2 ). Subjects are randomized using web-based randomization system in 1:1 ratio to the one of two arms: immediate ECMO therapy or early conservative therapy. In the invasive group, veno-arterial ECMO is inserted according to the local practice with flow settings to ensure sufficient tissue perfusion. All other diagnostic and therapeutic procedures including other cardiovascular interventions (i.e. percutaneous coronary intervention or cardiac surgery) are performed according to the current standard of care at the tertiary cardiovascular center. Acute implantation of other mechanical support devices (including ECMO in the conservative group) is allowed in the case of shock progression, ie. rapid deterioration of hemodynamic or metabolic status (defined as a need for increasing doses of vasopressors or a rise of serum lactate by 3 mmol/L within a minimum of 30 minutes after randomization). 
Patients must fulfil criteria for rapidly deteriorating (A) or severe (B) cardiogenic shock:
A. Rapidly deteriorating cardiogenic shock is defined as a progressive hemodynamic instability necessitating repeated bolus administration of vasopressors to maintain mean arterial pressure > 50 mmHg + impaired left ventricle systolic function (left ventricle ejection fraction (LVEF) < 35% or LVEF 35-55% in case of severe mitral regurgitation or aortic stenosis) B. Severe cardiogenic shock is defined by all following criteria:
Hemodynamic:
Cardiac Index (CI) < 2.2 L/min/m2 + norepinephrine dose > 0.1 μg/kg/min + dobutamine dose > 5 μg/kg/min or Systolic blood pressure < 100 mmHg + norepinephrine dose > 0.2 μg/kg/min + dobutamin dose > 5 μg/kg/min + (LVEF < 35% or LVEF 35-55% + severe mitral regurgitation or aortic stenosis)
Metabolic:
Lactate -two consecutive values ≥ 3 mmol/L (with at least 30 min interval between samples), with non-decreasing trend on steady doses of inotropes and/or vasopressors or SvO 2 -two consecutive values < 50% (with at least 30 min interval between samples), with non-increasing trend on steady doses of inotropes and/or vasopressors 3. Hypovolemia must be excluded:
Central venous pressure > 7 mmHg or pulmonary capillary wedge pressure > 12 mmHg All patients should provide written informed consent with the participation in the study. If patient status does not allow to give informed consent, it will be provided retrospectively after improvement of clinical conditions. If a patient deceases, remains unconscious or with significant brain dysfunction, written informed consent will be obtained from a patient's next of kin. If informed consent is not obtained, all acquired data will be removed from the database and will not be used in the analysis.
Endpoints
Primary endpoint is defined as a composite of death from any cause, resuscitated circulatory arrest, and implantation of another mechanical circulatory support device at 30 days. Secondary endpoints include all-cause mortality at 30 days, at 6 months and at 1 year, neurological outcome (according to Cerebral Performance Category scale) at 30 days, intensive care unit stay duration, hospital stay duration, need for intubation, renal replacement therapy and duration of mechanical ventilation.
Sample size was determined to detect clearly clinically significant 50% reduction of primary endpoint with 80% power at alpha = 0.05. The calculation indicates enrollment of 120 subjects (60 individuals in each arm). 
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Participating Centers
All participating sites are tertiary cardiovascular centers experienced in the management of severely compromised patients with cardiogenic shock and in the therapy with veno-arterial ECMO. All sites are fully equipped for the management of these patients according to the current standards of care and recommendations of the European Society of Cardiology. All sites offer 24/7 cathlab service for acute and emergency cases.
Conclusion
Despite the fact, that veno-arterial ECMO is increasingly used in the therapy of severe or rapidly progressing cardiogenic shock, current evidence for this strategy is clearly insufficient and data from a prospective randomized trial are lacking. The results of the ECMO-CS trial may significantly influence current practice in the management of patients with severe and deteriorating cardiogenic shock.
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